Wael Eid, MD
Endocrinology, Diabetes & Metabolism · Covington, KYNPI 1013936517
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.5%), food and beverage and education — rather than concentrated in one kind of arrangement. Amgen accounts for 63.9% of it on its own, with 54 other manufacturers making up the rest. Reporting peaked in 2019 at $19,477 and has fallen 90.6% since, to $1,833 in 2025.
Across 702 payments — averaging $43.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$20K
- Dexcom, Inc.$1K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Medtronic$853
- Novartis$755
- plus $6K from 49 others
Across 41 payments — averaging $11,669 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$418K
- Novartis$60K
- Eli Lilly$313
What the payments were for
- Speaking & faculty fees$17,70258%
- Travel & lodging$600%
- Food & beverage$12,93242%
- Education$760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,770 in reported general payments places this provider in the 85th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 73 | $2,158,114 |
| MounjaroTirzepatide | 1,084 | $1,411,933 |
| OzempicSemaglutide | 370 | $545,958 |
| Repatha SureclickEvolocumab | 420 | $399,422 |
| JardianceEmpagliflozin | 248 | $306,423 |
| Tresiba Flextouch U-200Insulin Degludec | 128 | $251,610 |
| TrulicityDulaglutide | 147 | $247,601 |
| Tresiba Flextouch U-100Insulin Degludec | 136 | $109,937 |
| FarxigaDapagliflozin Propanediol | 75 | $100,190 |
| Praluent PenAlirocumab | 96 | $94,432 |
| Novolog FlexpenInsulin Aspart | 260 | $89,911 |
| JanuviaSitagliptin Phosphate | 87 | $88,430 |
| Humalog Kwikpen U-100Insulin Lispro | 180 | $82,030 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 82 | $74,286 |
| ForteoTeriparatide | 18 | $73,984 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $635 | $2,158,11473 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $1,104 | $1,750,2081,290 claims |
| Novo NordiskOzempic, Wegovy, Novolog | $1,246 | $582,464441 claims |
| Boehringer IngelheimJardiance, Tradjenta | $238 | $327,129272 claims |
| AstraZenecaFarxiga | $180 | $100,19075 claims |
| Esperion Therapeutics, Inc.Nexletol | $44 | $17,01228 claims |
| AbbVieSynthroid | $330 | $10,910160 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Covington
- Yancey HolmesCovington$148K
- Linda HermillerCovington$12K
- Jaspreet ChahalCovington$11K
- Ailleen Heras HerzigCovington$5K
- Irina KorablevaCovington$4K
- Bradley EilermanFlorence$1.3M
- Sergio Chang FigueroaMadisonville$1.2M
- Hisham AlrefaiLouisville$720K
- Harold BaysLouisville$214K
- Jahangir CyrusLouisville$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.